Recent Posts
- Eyenovia Reveals Positive Evidence that Optejet® Delivery Technology Decreased Inflammation from Preserved Glaucoma Solutions Compared to Drops January 13, 2023
- Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation December 13, 2022
- Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund November 29, 2022
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com
Eyenovia Reveals Positive Evidence that Optejet® Delivery Technology Decreased Inflammation from Preserved Glaucoma Solutions Compared to Drops
NewsEyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
NewsEyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
NewsEyenovia announces positive results from VISION-2 Phase 3 Study of MicroLine as a potential on-demand treatment for presbyopia
NewsEyenovia announces planned retirement of Lead Independent Director Ken Lee, Jr.
NewsEyenovia to Participate in Multiple Medical Meetings in September
NewsEYENOVIA ANNOUNCES APPOINTMENT OF OPHTHALMIC INDUSTRY VETERAN MICHAEL ROWE AS CHIEF EXECUTIVE OFFICER AND BOARD MEMBER
NewsEYENOVIA PROVIDES MANUFACTURING UPDATE AND ANNOUNCES APPOINTMENT OF BREN KERN AS SVP OF MANUFACTURING AND OPERATIONS
NewsEYENOVIA ANNOUNCES APPOINTMENTS OF DR. ELLEN STRAHLMAN AND DR. RAM PALANKI AS NEW AND INDEPENDENT MEMBERS OF ITS BOARD OF DIRECTORS
NewsEyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
News